PUBLISHED DATE : Jul 2023 | Pages : 373
Fill out your details & get your free sample
The Active Pharmaceutical Ingredients (API) Market Size, Share, & Trends Analysis Report by
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2023–2028.
373 Pages
194 Tables
160 Charts
5 Regions
22 Countries
24 Companies
6 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size (2028) | USD 312.37 Billion |
| Market Size (2022) | USD 212.07 Billion |
| CAGR (2022-2028) | 6.67% |
| Base Year | 2022 |
| Forecast Year | 2023-2028 |
| Market Segments | Molecule Type, Therapy Area, Manufacturers Type, Brand, Potency, and Geography |
| Geographic Analysis | North America, Europe, APAC, Latin America, and Middle East & Africa |
| KEY PLAYERS | AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb Company, Cipla, Eli Lilly and Company, GSK, Merck KGaA, Novartis, Pfizer, Sanofi, Sun Pharmaceutical Industries, and Viatris |
The global active pharmaceutical ingredients (API) market was valued at USD 212.07 billion in 2022 and is expected to reach USD 312.37 billion by 2028, growing at a CAGR of 6.67%. Active Pharmaceutical Ingredients (API) are the active components of a drug, usually medicinal, specially designed to produce the desired pharmacological effect. They are responsible for a drug's therapeutic and physiological effects on its users. APIs are components of any medicinal product—whether in a finished dosage form such as a tablet, capsule, or injection or in a base drug substance form such as powder, liquid, or solid. Manufacturers in the active pharmaceutical ingredients (API) market are interested in registering a drug product that must have documented evidence that an API is of good quality and consistent performance.
Introducing an active pharmaceutical ingredient involves an evaluation of its composition, manufacture, and appropriate controls. Sources of APIs can range from bulk ingredients to pre-made formulations. APIs must meet certain regulatory requirements to be approved for use in pharmaceutical products. Such requirements include safety, efficacy, stability, and shelf life. Additionally, manufacturers in the active pharmaceutical ingredients (API) market must ensure that impurities and contaminants are kept within pre-specified limits for the product to meet its therapeutic requirements.
Reshaping the Pharmaceutical API Industry with Digital Transformation
Digital Transformation has allowed the active pharmaceutical ingredients (API) market to reshape itself to optimize production, streamline processes and reduce costs. By embracing the digital revolution, API manufacturers and suppliers can leverage advances in automated workflows, AI-enabled production management, and increased predictive analytics capabilities for data-driven decision-making. Additionally, the cloud-based infrastructure allows API-focused stakeholders to store, manage and use their data. At the same time, the increasing affordability of automation and other digital technologies helps to create a more efficient and cost-effective API supply chain more easily. Together, these advancements have enabled the pharmaceutical API industry to become more agile, responsive, and cost-efficient – unlocking new possibilities for product innovation and providing customers with a better overall experience.
Rising Demand for Novel APIs
The rising demand for novel APIs is due to the increasing need for newer, more specialized drugs to treat complex diseases, illnesses, and medical conditions. Novel APIs are developed using advanced biotechnologies and advanced synthesis techniques to create more effective drugs that provide better treatment than existing drugs. The growing demand for novel APIs is that they present several advantages over existing drugs, including improved safety, efficacy, and cost-effectiveness. Moreover, they can be used to treat rare diseases that current drugs cannot treat and to produce new therapies for existing diseases.
Technological Advancements API Manufacturing
The technological advancements in manufacturing in the active pharmaceutical ingredients (API) market have helped improve API quality, increase production efficiency, reduce costs, and ensure environmental protection. New technologies for API manufacturing include continuous processing and computerization of operations, which enable large-scale, cost-effective, and efficient production. Automated machines, computer-controlled process description (CPD) systems, and digital manufacturing systems are now being used to increase the accuracy of API formulation, improve overall efficiency, and reduce manual labor requirements. In addition, new technological advancements such as micronization techniques, nanotechnology, and crystallization techniques greatly improve API quality while increasing overall production speeds. Finally, new waste management methods, such as liquid waste treatments, have also significantly improved API manufacturing processes, as well as standards of environmental protection.
Growing Importance & Demand for Generic Drugs
Over recent years, the growing importance and demand for generic drugs have increased tremendously. This is mainly due to the cost savings they offer, as generic drugs typically cost 30-80% less than other brand-name drugs. Moreover, generic drugs are often the only option for patients who cannot afford expensive brand-name drugs. As such, generic drugs have become increasingly popular among consumers seeking affordable healthcare solutions. Additionally, generic drugs have become more widely available due to government programs like Medicaid and Medicare. These government-sponsored programs help to make generic drugs more accessible to those who need them. Furthermore, the increased demand for generic drugs has led to yet another significant development in the pharmaceutical industry: the formation of API manufacturers. These companies specialize in the production of APIs that are designed explicitly for generic medications. Creating APIs specifically tailored to generics can provide a cost-effective alternative to more expensive original drugs. As a result, manufacturers in the active pharmaceutical ingredients (API) market have become an essential component of the generic drug supply chain.
Growing API Outsourcing Operations
Outsourcing operations in the active pharmaceutical ingredients (API) market are particularly useful for pharmaceutical companies reducing costs and allowing them to focus on their core business, research, and development. This can also involve relocating manufacturing processes to lower-cost regions, helping to reduce overall costs. Outsourcing APIs can also help meet rapid demand for product launches, enabling faster turnaround times. The quality and safety of outsourced APIs must be closely monitored. The quality of APIs is critical during production and can determine the end product and its efficacy.
INSIGHTS BY MOLECULE TYPE
The global active pharmaceutical ingredients (API) market by molecule type is classified as large and small. This differentiation not only considers the size of the molecule but also how the molecules are made, their behavior, drug delivery, and mode of delivery. A small molecule API refers to an organic compound with a size of about 1 nm, which assists in regulating biological processes. Small molecules may be orally delivered, and the body is most likely to consume them. They possess the characteristics of rapid infusibility due to their small size, which enables them to reach the intercellular site of action. Small molecules have long been the basis for drug development. They are easily digested or absorbed into the bloodstream.
INSIGHTS BY THERAPY AREA
The cardiovascular therapy area dominated the global active pharmaceutical ingredients (API) market, accounting for a share of over 19% in 2022. Cardiovascular APIs are manufactured by companies involved in drug manufacturing for cardiovascular diseases. Manufacturers producing hypertensive drugs for people with high blood pressure drive the market's growth. Cardiovascular disease is a major cause of death and disability worldwide and is a major medical research and development focus. Pharmaceutical interventions are an important part of treatment for cardiovascular conditions, particularly when managing risk factors such as high blood pressure, high cholesterol, and diabetes. APIs are used to create medicines targeting specific aspects of the condition to achieve effective cardiovascular therapy.
Oncology therapy holds a significant share of the global active pharmaceutical ingredients (API) market. It is driven by the increasing incidence of cancer cases across the globe due to alarming environmental changes, the adoption of a sedentary lifestyle, and rising awareness amongst the population. Improved access to cancer care, including cancer prevention, screening treatment, and follow-up care, are some of the major factors contributing to the growth of the oncology therapy market. New targeted therapies for cancer are currently being focused upon in anti-cancer drug development.
INSIGHTS BY MANUFACTURERS TYPE
Based on the type of manufacturing process that an API-producing company opts for, the active pharmaceutical ingredients (API) market is segmented into captive and merchant markets. The captive market includes APIs produced by manufacturers in-house for their own needs, while the merchant market for APIs includes APIs manufactured by third parties. There are a lot of benefits and shortcomings of producing APIs in-house. COVID-19 has fueled the need for producing APIs in-house rather than outsourcing due to disruptions in the supply chain in China.
INSIGHTS BY BRAND
The patented/ innovative APIs segment accounted for a higher global active pharmaceutical ingredients (API) market in 2022. The use of patented or innovative active pharmaceutical ingredients (API) has become increasingly important in the pharmaceutical industry in recent years. Patented API can give a pharmaceutical company a competitive advantage through its exclusive access to the API, enabling it to sell products at higher margins and have a greater market share. API innovation is a necessary component of the pharmaceutical industry since it advances the development of new and improved pharmaceutical products that can benefit patients
INSIGHTS BY POTENCY
Active pharmaceutical ingredients (APIs) are essential components in producing pharmaceutical products. They are the active components in medicines that are responsible for the desired therapeutic effect. In recent years, the potency of APIs has become increasingly important for producing safe and effective medicines. Non-potent active pharmaceutical ingredients (NAPIs) are substances used as active ingredients in pharmaceuticals but do not possess the same potency as their potent counterparts (APIs). NAPIs are typically combined with APIs to enhance the drugs' therapeutic effect or reduce their toxicity. Low-potency NAPIs are generally considered safe for human consumption and are used to provide minor therapeutic benefits. The global non-potent active pharmaceutical ingredients (API) market is expected to grow at a CAGR of over 6% during the forecast period.
North America is one of the largest global active pharmaceutical ingredients (API) markets, accounting for over 41% share in 2022. The region has seen a steady growth in the demand for APIs, driven primarily by the increasing prevalence of chronic diseases, the rising demand for generic drugs, and the rapid development of the pharmaceutical industry. The increasing number of chronic diseases in North America has been a major factor driving the demand for APIs. According to the Centers for Disease Control and Prevention (CDC), around half of the adults in the U.S. suffer from at least one chronic disease. This has led to an increase in the use of prescription drugs, which in turn has led to an increase in the demand for APIs.
APAC is a major player in the global active pharmaceutical ingredients (API) market, producing a large proportion of the APIs used to manufacture medicines worldwide. In terms of global production, China and India lead the way in terms of volume, followed by South Korea and Japan. To ensure the safety of the APIs produced in the region, government agencies in various countries have implemented various regulations and measures to ensure their quality and safety. These measures include implementing quality assurance systems, good manufacturing practices, and inspection of API manufacturing sites.
The active pharmaceutical ingredients (API) market is concentrated, competitive, and characterized by numerous global and domestic vendors across geographies. AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb Company, Cipla, Eli Lilly and Company, GSK, Merck KGaA, Novartis, Pfizer, Sanofi, Sun Pharmaceuticals, and Viatris are the prominent vendors in the global active pharmaceutical ingredients (API) market. These companies are always at the forefront of delivering high-quality APIs for domestic and international pharmaceutical manufacturers. They also invest in considerable R&D activities to offer a competitive product line.
Due to the highly competitive and volatile environment in the market, companies have started focusing on sustainability with a commitment to generate more value from fewer resources. Also, several companies focus on turning environmental challenges and societal concerns into product innovations. Key players such as Pfizer and Novartis are involved in several ongoing green chemistry initiatives and sustainability partnerships with government bodies across the globe. Sustainability has emerged as a fundamental strategic approach for vendors to gain a competitive edge in the market.
Frequently Asked Questions
How big is the active pharmaceutical ingredients (API) market?
The global active pharmaceutical ingredients (API) market size was valued at USD 212.07 billion in 2022 and is expected to reach USD 312.37 billion by 2028.
What is the growth rate of the global active pharmaceutical ingredients (API) market?
The global active pharmaceutical ingredients (API) market share is growing at a CAGR of 6.67% from 2022-2028.
What are the growing trends in the active pharmaceutical ingredients (API) market?
The growing trends in the active pharmaceutical ingredients (API) market are reshaping the pharmaceutical API industry with digital transformation, increasing the adoption of biosimilars, and rising demand for novel APIs.
Which region holds the most significant global active pharmaceutical ingredients (API) market share?
North America dominated the global active pharmaceutical ingredients (API) market share, accounting for over 41% in 2022.
Who are the key players in the global active pharmaceutical ingredients (API) market?
AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb Company, Cipla, Eli Lilly and Company, GSK, Merck KGaA, Novartis, Pfizer, Sanofi, Sun Pharmaceutical Industries, and Viatris are the key players in the global active pharmaceutical ingredients (API) market.
The global active pharmaceutical ingredients (API) market size is expected to grow at a CAGR of approximately 6.67% from 2022 to 2028.
The following factors are likely to contribute to the growth of the global active pharmaceutical ingredients (API) market during the forecast period:
Base Year: 2022
Forecast Year: 2023-2028
The report considers the present scenario of the active pharmaceutical ingredients (API) market and its market dynamics for 2023−2028. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the industry. It also profiles and analyzes leading companies and several other prominent companies operating in the market.
Key Company Profiles
Other Prominent Vendors
Segmentation by Molecule Type
Segmentation by Therapy Area
Segmentation by Manufacturers Type
Segmentation by Brand
Segmentation by Potency
Segmentation by Geography
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY MOLECULE TYPE
4.3.2 MARKET SEGMENTATION BY THERAPY AREA
4.3.3 MARKET SEGMENTATION BY MANUFACTURER TYPE
4.3.4 MARKET SEGMENTATION BY BRAND
4.3.5 MARKET SEGMENTATION BY POTENCY
4.3.6 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 PREMIUM INSIGHTS
7.1 OVERVIEW
7.1.1 GEOGRAPHY INSIGHTS
7.1.2 MOLECULE TYPE SEGMENTATION INSIGHTS
7.1.3 THERAPY AREA SEGMENTATION INSIGHTS
7.1.4 MANUFACTURER TYPE SEGMENTATION INSIGHTS
7.1.5 BRAND SEGMENTATION INSIGHTS
7.1.6 POTENCY SEGMENTATION INSIGHTS
8 INTRODUCTION
8.1 OVERVIEW
8.1.1 IMPACT OF COVID-19
9 MARKET OPPORTUNITIES & TRENDS
9.1 DIGITAL TRANSFORMATION OF PHARMACEUTICAL API INDUSTRY
9.2 INCREASED ADOPTION OF BIOSIMILARS
9.3 DEMAND FOR NOVEL APIS
10 MARKET GROWTH ENABLERS
10.1 TECHNOLOGICAL ADVANCES IN API MANUFACTURING
10.2 DEMAND FOR GENERIC DRUGS
10.3 GROWTH OF PHARMACEUTICAL INDUSTRY
10.4 INCREASED API OUTSOURCING OPERATIONS
11 MARKET RESTRAINTS
11.1 STRINGENT GOVERNMENT REGULATIONS
11.2 LOW PROFIT MARGINS & HIGH API-MANUFACTURING COSTS
11.3 ANALYTICAL CHALLENGES IN TESTING PROCESSES
12 MARKET LANDSCAPE
12.1 MARKET OVERVIEW
12.2 MARKET SIZE & FORECAST
12.3 MARKET OPPORTUNITY
12.3.1 MARKET BY MOLECULE TYPE
12.3.2 MARKET BY THERAPY AREA
12.3.3 MARKET BY MANUFACTURER TYPE
12.3.4 MARKET BY BRAND
12.3.5 MARKET BY POTENCY
12.3.6 MARKET BY GEOGRAPHY
12.4 FIVE FORCES ANALYSIS
12.4.1 THREAT OF NEW ENTRANTS
12.4.2 BARGAINING POWER OF SUPPLIERS
12.4.3 BARGAINING POWER OF BUYERS
12.4.4 THREAT OF SUBSTITUTES
12.4.5 COMPETITIVE RIVALRY
13 MOLECULE TYPE
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 SMALL MOLECULES/CHEMICAL APIS
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.3.3 SMALL MOLECULES/CHEMICAL APIS BY GEOGRAPHY
13.4 LARGE MOLECULES/BIOLOGICAL APIS
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.4.3 LARGE MOLECULES/BIOLOGICAL APIS BY GEOGRAPHY
14 THERAPY AREA
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 CARDIOVASCULAR
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.3.3 CARDIOVASCULAR BY GEOGRAPHY
14.4 ONCOLOGY
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.4.3 ONCOLOGY BY GEOGRAPHY
14.5 NEUROLOGY
14.5.1 MARKET OVERVIEW
14.5.2 MARKET SIZE & FORECAST
14.5.3 NEUROLOGY BY GEOGRAPHY
14.6 ANTI-INFECTIVES
14.6.1 MARKET OVERVIEW
14.6.2 MARKET SIZE & FORECAST
14.6.3 ANTI-INFECTIVES BY GEOGRAPHY
14.7 ENDOCRINOLOGY
14.7.1 MARKET OVERVIEW
14.7.2 MARKET SIZE & FORECAST
14.7.3 ENDOCRINOLOGY BY GEOGRAPHY
14.8 PULMONOLOGY
14.8.1 MARKET OVERVIEW
14.8.2 MARKET SIZE & FORECAST
14.8.3 PULMONOLOGY BY GEOGRAPHY
14.9 OTHER THERAPY AREAS
14.9.1 MARKET OVERVIEW
14.9.2 MARKET SIZE & FORECAST
14.9.3 OTHER THERAPY AREAS BY GEOGRAPHY
15 MANUFACTURER TYPE
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 CAPTIVE
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.3.3 CAPTIVE BY GEOGRAPHY
15.4 MERCHANT
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
15.4.3 MERCHANT BY GEOGRAPHY
16 BRAND
16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 MARKET OVERVIEW
16.3 PATENTED/INNOVATIVE APIS
16.3.1 MARKET OVERVIEW
16.3.2 MARKET SIZE & FORECAST
16.3.3 PATENTED/INNOVATIVE APIS BY GEOGRAPHY
16.4 GENERIC APIS
16.4.1 MARKET OVERVIEW
16.4.2 MARKET SIZE & FORECAST
16.4.3 GENERIC APIS BY GEOGRAPHY
17 POTENCY
17.1 MARKET SNAPSHOT & GROWTH ENGINE
17.2 MARKET OVERVIEW
17.3 NON-POTENT APIS
17.3.1 MARKET OVERVIEW
17.3.2 MARKET SIZE & FORECAST
17.3.3 NON-POTENT APIS BY GEOGRAPHY
17.4 HIGHLY POTENT APIS
17.4.1 MARKET OVERVIEW
17.4.2 MARKET SIZE & FORECAST
17.4.3 HIGHLY POTENT APIS BY GEOGRAPHY
18 GEOGRAPHY
18.1 MARKET SNAPSHOT & GROWTH ENGINE
18.2 GEOGRAPHIC OVERVIEW
19 NORTH AMERICA
19.1 MARKET OVERVIEW
19.2 MARKET SIZE & FORECAST
19.2.1 NORTH AMERICA: MARKET BY MOLECULE TYPE
19.2.2 NORTH AMERICA: MARKET BY THERAPY AREA
19.2.3 NORTH AMERICA: MARKET BY MANUFACTURER TYPE
19.2.4 NORTH AMERICA: MARKET BY BRAND
19.2.5 NORTH AMERICA: MARKET BY POTENCY
19.3 KEY COUNTRIES
19.3.1 US: MARKET SIZE & FORECAST
19.3.2 CANADA: MARKET SIZE & FORECAST
20 APAC
20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
20.2.1 APAC: MARKET BY MOLECULE TYPE
20.2.2 APAC: MARKET BY THERAPY AREA
20.2.3 APAC: MARKET BY MANUFACTURER TYPE
20.2.4 APAC: MARKET BY BRAND
20.2.5 APAC: MARKET BY POTENCY
20.3 KEY COUNTRIES
20.3.1 CHINA: MARKET SIZE & FORECAST
20.3.2 INDIA: MARKET SIZE & FORECAST
20.3.3 JAPAN: MARKET SIZE & FORECAST
20.3.4 SOUTH KOREA: MARKET SIZE & FORECAST
20.3.5 AUSTRALIA: MARKET SIZE & FORECAST
20.3.6 INDONESIA: MARKET SIZE & FORECAST
20.3.7 SINGAPORE: MARKET SIZE & FORECAST
21 EUROPE
21.1 MARKET OVERVIEW
21.2 MARKET SIZE & FORECAST
21.2.1 EUROPE: MARKET BY MOLECULE TYPE
21.2.2 EUROPE: MARKET BY THERAPY AREA
21.2.3 EUROPE: MARKET BY MANUFACTURER TYPE
21.2.4 EUROPE: MARKET BY BRAND
21.2.5 EUROPE: MARKET BY POTENCY
21.3 KEY COUNTRIES
21.3.1 GERMANY: MARKET SIZE & FORECAST
21.3.2 UK: MARKET SIZE & FORECAST
21.3.3 RUSSIA: MARKET SIZE & FORECAST
21.3.4 FRANCE: MARKET SIZE & FORECAST
21.3.5 SPAIN: MARKET SIZE & FORECAST
21.3.6 ITALY: MARKET SIZE & FORECAST
22 LATIN AMERICA
22.1 MARKET OVERVIEW
22.2 MARKET SIZE & FORECAST
22.2.1 LATIN AMERICA: MARKET BY MOLECULE TYPE
22.2.2 LATIN AMERICA: MARKET BY THERAPY AREA
22.2.3 LATIN AMERICA: MARKET BY MANUFACTURER TYPE
22.2.4 LATIN AMERICA: MARKET BY BRAND
22.2.5 LATIN AMERICA: MARKET BY POTENCY
22.3 KEY COUNTRIES
22.3.1 BRAZIL: MARKET SIZE & FORECAST
22.3.2 MEXICO: MARKET SIZE & FORECAST
22.3.3 ARGENTINA: MARKET SIZE & FORECAST
23 MIDDLE EAST & AFRICA
23.1 MARKET OVERVIEW
23.2 MARKET SIZE & FORECAST
23.2.1 MIDDLE EAST & AFRICA: MARKET BY MOLECULE TYPE
23.2.2 MIDDLE EAST & AFRICA: MARKET BY THERAPY AREA
23.2.3 MIDDLE EAST & AFRICA: MARKET BY MANUFACTURER TYPE
23.2.4 MIDDLE EAST & AFRICA: MARKET BY BRAND
23.2.5 MIDDLE EAST & AFRICA: MARKET BY POTENCY
23.3 KEY COUNTRIES
23.3.1 TURKEY: MARKET SIZE & FORECAST
23.3.2 SAUDI ARABIA: MARKET SIZE & FORECAST
23.3.3 UAE: MARKET SIZE & FORECAST
23.3.4 SOUTH AFRICA: MARKET SIZE & FORECAST
24 COMPETITIVE LANDSCAPE
24.1 COMPETITION OVERVIEW
24.1.1 RECENT KEY ACTIVITIES IN GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
24.2 MARKET SHARE ANALYSIS
24.2.1 ABBVIE
24.2.2 BOEHRINGER INGELHEIM
24.2.3 BRISTOL-MYERS SQUIBB COMPANY
24.2.4 CIPLA
24.2.5 ELI LILLY AND COMPANY
24.2.6 GSK
24.2.7 MERCK KGAA
24.2.8 NOVARTIS
24.2.9 PFIZER
24.2.10 SANOFI
24.2.11 SUN PHARMACEUTICAL INDUSTRIES
24.2.12 VIATRIS
25 KEY COMPANY PROFILES
25.1 ABBVIE
25.1.1 BUSINESS OVERVIEW
25.1.2 PRODUCT OFFERINGS
25.1.3 KEY STRATEGIES
25.1.4 KEY STRENGTHS
25.1.5 KEY OPPORTUNITIES
25.2 BOEHRINGER INGELHEIM
25.2.1 BUSINESS OVERVIEW
25.2.2 PRODUCT OFFERINGS
25.2.3 KEY STRATEGIES
25.2.4 KEY STRENGTHS
25.2.5 KEY OPPORTUNITIES
25.3 BRISTOL-MYERS SQUIBB COMPANY
25.3.1 BUSINESS OVERVIEW
25.3.2 PRODUCT OFFERINGS
25.3.3 KEY STRATEGIES
25.3.4 KEY STRENGTHS
25.3.5 KEY OPPORTUNITIES
25.4 CIPLA
25.4.1 BUSINESS OVERVIEW
25.4.2 PRODUCT OFFERINGS
25.4.3 KEY STRATEGIES
25.4.4 KEY STRENGTHS
25.4.5 KEY OPPORTUNITIES
25.5 ELI LILLY AND COMPANY
25.5.1 BUSINESS OVERVIEW
25.5.2 PRODUCT OFFERINGS
25.5.3 KEY STRATEGIES
25.5.4 KEY STRENGTHS
25.5.5 KEY OPPORTUNITIES
25.6 GSK
25.6.1 BUSINESS OVERVIEW
25.6.2 PRODUCT OFFERINGS
25.6.3 KEY STRATEGIES
25.6.4 KEY STRENGTHS
25.6.5 KEY OPPORTUNITIES
25.7 MERCK KGAA
25.7.1 BUSINESS OVERVIEW
25.7.2 PRODUCT OFFERINGS
25.7.3 KEY STRATEGIES
25.7.4 KEY STRENGTHS
25.7.5 KEY OPPORTUNITIES
25.8 NOVARTIS
25.8.1 BUSINESS OVERVIEW
25.8.2 PRODUCT OFFERINGS
25.8.3 KEY STRATEGIES
25.8.4 KEY STRENGTHS
25.8.5 KEY OPPORTUNITIES
25.9 PFIZER
25.9.1 BUSINESS OVERVIEW
25.9.2 PRODUCT OFFERINGS
25.9.3 KEY STRATEGIES
25.9.4 KEY STRENGTHS
25.9.5 KEY OPPORTUNITIES
25.10 SANOFI
25.10.1 BUSINESS OVERVIEW
25.10.2 PRODUCT OFFERINGS
25.10.3 KEY STRATEGIES
25.10.4 KEY STRENGTHS
25.10.5 KEY OPPORTUNITIES
25.11 SUN PHARMACEUTICAL INDUSTRIES
25.11.1 BUSINESS OVERVIEW
25.11.2 PRODUCT OFFERINGS
25.11.3 KEY STRATEGIES
25.11.4 KEY STRENGTHS
25.11.5 KEY OPPORTUNITIES
25.12 VIATRIS
25.12.1 BUSINESS OVERVIEW
25.12.2 PRODUCT OFFERINGS
25.12.3 KEY STRATEGIES
25.12.4 KEY STRENGTHS
25.12.5 KEY OPPORTUNITIES
26 OTHER PROMINENT VENDORS
26.1 ABBOTT
26.1.1 BUSINESS OVERVIEW
26.1.2 KEY HIGHLIGHTS
26.2 ALBEMARLE CORPORATION
26.2.1 BUSINESS OVERVIEW
26.2.2 KEY HIGHLIGHTS
26.3 AMGEN
26.3.1 BUSINESS OVERVIEW
26.3.2 KEY HIGHLIGHTS
26.4 AUROBINDO PHARMA
26.4.1 BUSINESS OVERVIEW
26.4.2 KEY HIGHLIGHTS
26.5 BASF CORPORATION
26.5.1 BUSINESS OVERVIEW
26.5.2 KEY HIGHLIGHTS
26.6 BIOCON
26.6.1 BUSINESS OVERVIEW
26.6.2 KEY HIGHLIGHTS
26.7 DR. REDDY’S LABORATORIES
26.7.1 BUSINESS OVERVIEW
26.7.2 KEY HIGHLIGHTS
26.8 TEVA PHARMACEUTICAL INDUSTRIES
26.8.1 BUSINESS OVERVIEW
26.8.2 KEY HIGHLIGHTS
26.9 F. HOFFMANN-LA ROCHE
26.9.1 BUSINESS OVERVIEW
26.9.2 KEY HIGHLIGHTS
26.10 GLENMARK PHARMACEUTICALS
26.10.1 BUSINESS OVERVIEW
26.10.2 KEY HIGHLIGHTS
26.11 LUPIN
26.11.1 BUSINESS OVERVIEW
26.11.2 KEY HIGHLIGHTS
26.12 SHENZHEN HEPALINK PHARMACEUTICAL GROUP
26.12.1 BUSINESS OVERVIEW
26.12.2 KEY HIGHLIGHTS
27 REPORT SUMMARY
27.1 KEY TAKEAWAYS
27.2 STRATEGIC RECOMMENDATIONS
28 QUANTITATIVE SUMMARY
28.1 MARKET BY MOLECULE TYPE
28.1.1 NORTH AMERICA: MARKET BY MOLECULE TYPE
28.1.2 APAC: MARKET BY MOLECULE TYPE
28.1.3 EUROPE: MARKET BY MOLECULE TYPE
28.1.4 LATIN AMERICA: MARKET BY MOLECULE TYPE
28.1.5 MIDDLE EAST & AFRICA: MARKET BY MOLECULE TYPE
28.2 MARKET BY THERAPY AREA
28.2.1 NORTH AMERICA: MARKET BY THERAPY AREA
28.2.2 APAC: MARKET BY THERAPY AREA
28.2.3 EUROPE: MARKET BY THERAPY AREA
28.2.4 LATIN AMERICA: MARKET BY THERAPY AREA SEGMENTATION
28.2.5 MIDDLE EAST & AFRICA: MARKET BY THERAPY AREA
28.3 MARKET BY MANUFACTURER TYPE
28.3.1 NORTH AMERICA: MARKET BY MANUFACTURER TYPE SEGMENTATION
28.3.2 APAC: MARKET BY MANUFACTURER TYPE
28.3.3 EUROPE: MARKET BY MANUFACTURER TYPE SEGMENTATION
28.3.4 LATIN AMERICA: MARKET BY MANUFACTURER TYPE SEGMENTATION
28.3.5 MIDDLE EAST & AFRICA: MARKET BY MANUFACTURER TYPE
28.4 MARKET BY BRAND
28.4.1 NORTH AMERICA: MARKET BY BRAND
28.4.2 APAC: MARKET BY BRAND
28.4.3 EUROPE: MARKET BY BRAND
28.4.4 LATIN AMERICA: MARKET BY BRAND
28.4.5 MIDDLE EAST & AFRICA: MARKET BY BRAND
28.5 MARKET BY POTENCY
28.5.1 NORTH AMERICA: MARKET BY POTENCY
28.5.2 APAC: MARKET BY POTENCY
28.5.3 EUROPE: MARKET BY POTENCY
28.5.4 LATIN AMERICA: MARKET BY POTENCY SEGMENTATION
28.5.5 MIDDLE EAST & AFRICA: MARKET BY POTENCY
28.6 MARKET BY GEOGRAPHY
28.6.1 SMALL MOLECULES/CHEMICAL APIS BY GEOGRAPHY
28.6.2 LARGE MOLECULES/BIOLOGICAL APIS BY GEOGRAPHY
28.6.3 CARDIOVASCULAR BY GEOGRAPHY
28.6.4 ONCOLOGY BY GEOGRAPHY
28.6.5 NEUROLOGY BY GEOGRAPHY
28.6.6 ANTI-INFECTIVES BY GEOGRAPHY
28.6.7 ENDOCRINOLOGY BY GEOGRAPHY
28.6.8 PULMONOLOGY BY GEOGRAPHY
28.6.9 OTHER THERAPY AREAS BY GEOGRAPHY
28.6.10 CAPTIVE BY GEOGRAPHY
28.6.11 MERCHANT BY GEOGRAPHY
28.6.12 PATENTED/INNOVATIVE APIS BY GEOGRAPHY
28.6.13 GENERIC APIS BY GEOGRAPHY
28.6.14 NON-POTENT APIS BY GEOGRAPHY
28.6.15 HIGHLY POTENT APIS BY GEOGRAPHY
29 APPENDIX
29.1 ABBREVIATIONS
EXHIBIT 1 SEGMENTATION OF GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH (2022)
EXHIBIT 3 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY: MARKET SHARE 2022–2028 (%)
EXHIBIT 4 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE: MARKET SHARE 2022–2028 (%)
EXHIBIT 5 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA: MARKET SHARE 2022–2028 (%)
EXHIBIT 6 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE: MARKET SHARE 2022–2028 (%)
EXHIBIT 7 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND: MARKET SHARE 2022–2028 (%)
EXHIBIT 8 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY: MARKET SHARE 2022–2028 (%)
EXHIBIT 9 BIOTECH API MANUFACTURING PROCESS
EXHIBIT 10 SYNTHETIC API MANUFACTURING PROCESS
EXHIBIT 11 IMPACT OF DIGITAL TRANSFORMATION OF PHARMACEUTICAL API INDUSTRY
EXHIBIT 12 BENEFITS OF DIGITAL TRANSFORMATION FOR BUSINESS DEVELOPERS
EXHIBIT 13 IMPACT OF INCREASED ADOPTION OF BIOSIMILARS
EXHIBIT 14 IMPACT OF DEMAND FOR NOVEL APIS
EXHIBIT 15 GLOBAL LAUNCHES OF NOVEL ACTIVE SUBSTANCES (NASS) 2013–2022
EXHIBIT 16 IMPACT OF TECHNOLOGICAL ADVANCES IN API MANUFACTURING
EXHIBIT 17 IMPACT OF DEMAND FOR GENERIC DRUGS
EXHIBIT 18 PENETRATION RATE OF GENERICS BY COUNTRIES IN 2019 (%)
EXHIBIT 19 GENERICS OPPORTUNITY BASED ON PATENT EXPIRATION BETWEEN 2020 AND 2026 BY THERAPY AREA (%)
EXHIBIT 20 IMPACT OF GROWTH OF PHARMACEUTICAL INDUSTRY
EXHIBIT 21 GLOBAL PHARMACEUTICAL INDUSTRY SIZE 2015–2025 ($ BILLION)
EXHIBIT 22 GLOBAL APIS MANUFACTURERS: R&D EXPENDITURE 2020–2022 ($ MILLION)
EXHIBIT 23 IMPACT OF INCREASED API OUTSOURCING OPERATIONS
EXHIBIT 24 IMPACT OF STRINGENT GOVERNMENT REGULATIONS
EXHIBIT 25 IMPACT OF LOW PROFIT MARGINS & HIGH API-MANUFACTURING COSTS
EXHIBIT 26 IMPACT OF ANALYTICAL CHALLENGES IN TESTING PROCESSES
EXHIBIT 27 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 28 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE: MARKET OPPORTUNITY
EXHIBIT 29 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA: MARKET OPPORTUNITY
EXHIBIT 30 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE: MARKET OPPORTUNITY
EXHIBIT 31 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND: MARKET OPPORTUNITY
EXHIBIT 32 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY: MARKET OPPORTUNITY
EXHIBIT 33 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY: MARKET OPPORTUNITY
EXHIBIT 34 FIVE FORCES ANALYSIS 2022
EXHIBIT 35 INCREMENTAL GROWTH BY MOLECULE TYPE 2022 & 2028
EXHIBIT 36 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 37 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE: ABSOLUTE GROWTH (%)
EXHIBIT 38 GLOBAL SMALL MOLECULES/ CHEMICAL APIS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 39 GLOBAL SMALL MOLECULES/CHEMICAL APIS MARKET 2022–2028 ($ BILLION)
EXHIBIT 40 GLOBAL LARGE MOLECULES/ BIOLOGICAL APIS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 41 GLOBAL LARGE MOLECULES/BIOLOGICAL APIS 2022–2028 ($ BILLION)
EXHIBIT 42 INCREMENTAL GROWTH BY THERAPY AREA 2022 & 2028
EXHIBIT 43 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 44 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA: ABSOLUTE GROWTH (%)
EXHIBIT 45 GLOBAL CARDIOVASCULAR ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 46 GLOBAL CARDIOVASCULAR ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 47 GLOBAL ONCOLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 48 GLOBAL ONCOLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 49 GLOBAL NEUROLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 50 GLOBAL NEUROLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 51 GLOBAL ANTI-INFECTIVES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 52 GLOBAL ANTI-INFECTIVES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 53 GLOBAL ENDOCRINOLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 54 GLOBAL ENDOCRINOLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 55 GLOBAL PULMONOLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 56 GLOBAL PULMONOLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 57 GLOBAL OTHER THERAPY AREAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 58 GLOBAL OTHER THERAPY AREAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 59 INCREMENTAL GROWTH BY MANUFACTURER TYPE 2022 & 2028
EXHIBIT 60 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 61 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE: ABSOLUTE GROWTH (%)
EXHIBIT 62 GLOBAL CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 63 GLOBAL CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 64 GLOBAL MERCHANT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 65 GLOBAL MERCHANT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 66 INCREMENTAL GROWTH BY BRAND 2022 & 2028
EXHIBIT 67 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 68 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND: ABSOLUTE GROWTH (%)
EXHIBIT 69 GLOBAL PATENTED/INNOVATIVE APIS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 70 GLOBAL PATENTED/INNOVATIVE APIS MARKET 2022–2028 ($ BILLION)
EXHIBIT 71 GLOBAL GENERIC APIS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 72 GLOBAL GENERIC APIS MARKET 2022–2028 ($ BILLION)
EXHIBIT 73 INCREMENTAL GROWTH BY POTENCY 2022 & 2028
EXHIBIT 74 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 75 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY: ABSOLUTE GROWTH (%)
EXHIBIT 76 GLOBAL NON-POTENT APIS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 77 GLOBAL NON-POTENT APIS MARKET 2022–2028 ($ BILLION)
EXHIBIT 78 GLOBAL HIGHLY POTENT APIS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 79 GLOBAL HIGHLY POTENT APIS MARKET 2022–2028 ($ BILLION)
EXHIBIT 80 INCREMENTAL GROWTH BY GEOGRAPHY 2022 & 2028
EXHIBIT 81 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 82 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY: ABSOLUTE GROWTH (%)
EXHIBIT 83 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: KEY COUNTRIES IN 2022 ($ BILLION)
EXHIBIT 84 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: KEY COUNTRIES ($ BILLION)
EXHIBIT 85 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 86 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 87 INCREMENTAL GROWTH IN NORTH AMERICA 2022 & 2028
EXHIBIT 88 US ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 89 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 90 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: KEY COUNTRIES ($ BILLION)
EXHIBIT 91 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 92 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 93 INCREMENTAL GROWTH IN APAC 2022 & 2028
EXHIBIT 94 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 95 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 96 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 97 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 98 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 99 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 100 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 101 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: KEY COUNTRIES ($ BILLION)
EXHIBIT 102 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 103 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 104 INCREMENTAL GROWTH IN EUROPE 2022 & 2028
EXHIBIT 105 GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 106 UK ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 107 RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 108 FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 109 SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 110 ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 111 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: KEY COUNTRIES ($ BILLION)
EXHIBIT 112 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 113 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 114 INCREMENTAL GROWTH IN LATIN AMERICA 2022 & 2028
EXHIBIT 115 BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 116 MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 117 ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 118 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: KEY COUNTRIES ($ BILLION)
EXHIBIT 119 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 120 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 121 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2022 & 2028
EXHIBIT 122 TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 123 SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 124 UAE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 125 SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2022–2028 ($ BILLION)
EXHIBIT 126 ABBVIE: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 127 ABBVIE: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 128 BOEHRINGER INGELHEIM: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 129 BOEHRINGER INGELHEIM: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 130 BOEHRINGER INGELHEIM: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 131 BOEHRINGER INGELHEIM: REVENUE BY GEOGRAPHIC REGION 2022 ($ BILLION)
EXHIBIT 132 BRISTOL-MYERS SQUIBB COMPANY: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 133 BRISTOL-MYERS SQUIBB COMPANY: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 134 ELI LILLY AND COMPANY: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 135 ELI LILLY AND COMPANY: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 136 ELI LILLY AND COMPANY: REVENUE BY GEOGRAPHIC REGION 2022 ($ BILLION)
EXHIBIT 137 GSK: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 138 GSK: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 139 MERCK KGAA: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 140 MERCK KGAA: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 141 MERCK KGAA: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 142 MERCK KGAA: REVENUE BY GEOGRAPHIC REGION 2022 ($ BILLION)
EXHIBIT 143 NOVARTIS: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 144 NOVARTIS: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 145 NOVARTIS: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 146 NOVARTIS: REVENUE BY GEOGRAPHY 2022 ($ BILLION)
EXHIBIT 147 PFIZER: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 148 PFIZER: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 149 PFIZER: REVENUE BY BUSINESS SEGMENT 2021 ($ BILLION)
EXHIBIT 150 PFIZER: REVENUE BY GEOGRAPHIC REGION 2021 ($ BILLION)
EXHIBIT 151 SANOFI: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 152 SANOFI: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 153 SANOFI: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 154 SANOFI: REVENUE BY GEOGRAPHIC REGION 2022 ($ BILLION)
EXHIBIT 155 SUN PHARMACEUTICAL INDUSTRIES: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 156 SUN PHARMACEUTICAL INDUSTRIES: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 157 VIATRIS: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 158 VIATRIS: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 159 VIATRIS: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 160 VIATRIS: REVENUE BY GEOGRAPHIC REGION 2022 ($ BILLION)
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2016–2022
TABLE 3 SUMMARY OF CROSS-COUNTRY ANALYSIS
TABLE 4 NUMBER OF BLOCKBUSTER & SMALL-MOLECULE DRUGS GOING-OFF PATENT GLOBALLY
TABLE 5 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE: MARKET SIZE 2022 & 2028
TABLE 6 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA: MARKET SIZE 2022 & 2028
TABLE 7 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE: MARKET SIZE 2022 & 2028
TABLE 8 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND: MARKET SIZE 2022 & 2028
TABLE 9 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY: MARKET SIZE 2022 & 2028
TABLE 10 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY: MARKET SIZE 2022 & 2028
TABLE 11 GLOBAL SMALL MOLECULES/CHEMICAL APIS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 12 GLOBAL SMALL MOLECULES/CHEMICAL APIS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 13 GLOBAL LARGE MOLECULES/BIOLOGICAL APIS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 14 GLOBAL LARGE MOLECULES/BIOLOGICAL APIS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 15 GLOBAL CARDIOVASCULAR ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 16 GLOBAL CARDIOVASCULAR ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 17 GLOBAL ONCOLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 18 GLOBAL ONCOLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 19 GLOBAL NEUROLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 20 GLOBAL NEUROLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 21 GLOBAL ANTI-INFECTIVES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 22 GLOBAL ANTI-INFECTIVES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 23 GLOBAL ENDOCRINOLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 24 GLOBAL ENDOCRINOLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 25 GLOBAL PULMONOLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 26 GLOBAL PULMONOLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 27 GLOBAL OTHER THERAPY AREAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 28 GLOBAL OTHER THERAPY AREAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 29 GLOBAL CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 30 GLOBAL CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 31 GLOBAL MERCHANT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 32 GLOBAL MERCHANT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 33 GLOBAL PATENTED/INNOVATIVE APIS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 34 GLOBAL PATENTED/INNOVATIVE APIS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 35 GLOBAL GENERIC APIS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 36 GLOBAL GENERIC APIS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 37 GLOBAL NON-POTENT APIS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 38 GLOBAL NON-POTENT APIS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 39 GLOBAL HIGHLY POTENT APIS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 40 GLOBAL HIGHLY POTENT APIS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 41 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 ($ BILLION)
TABLE 42 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 (%)
TABLE 43 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 ($ BILLION)
TABLE 44 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 (%)
TABLE 45 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 ($ BILLION)
TABLE 46 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 (%)
TABLE 47 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 ($ BILLION)
TABLE 48 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 (%)
TABLE 49 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 ($ BILLION)
TABLE 50 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 (%)
TABLE 51 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 ($ BILLION)
TABLE 52 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 (%)
TABLE 53 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 ($ BILLION)
TABLE 54 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 (%)
TABLE 55 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 ($ BILLION)
TABLE 56 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 (%)
TABLE 57 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 ($ BILLION)
TABLE 58 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 (%)
TABLE 59 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 ($ BILLION)
TABLE 60 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 (%)
TABLE 61 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 ($ BILLION)
TABLE 62 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 (%)
TABLE 63 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 ($ BILLION)
TABLE 64 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 (%)
TABLE 65 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 ($ BILLION)
TABLE 66 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 (%)
TABLE 67 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 ($ BILLION)
TABLE 68 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 (%)
TABLE 69 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 ($ BILLION)
TABLE 70 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 (%)
TABLE 71 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 ($ BILLION)
TABLE 72 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 (%)
TABLE 73 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 ($ BILLION)
TABLE 74 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 (%)
TABLE 75 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 ($ BILLION)
TABLE 76 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 (%)
TABLE 77 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 ($ BILLION)
TABLE 78 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 (%)
TABLE 79 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 ($ BILLION)
TABLE 80 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 (%)
TABLE 81 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 ($ BILLION)
TABLE 82 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 (%)
TABLE 83 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 ($ BILLION)
TABLE 84 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 (%)
TABLE 85 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 ($ BILLION)
TABLE 86 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 (%)
TABLE 87 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 ($ BILLION)
TABLE 88 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 (%)
TABLE 89 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 ($ BILLION)
TABLE 90 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 (%)
TABLE 91 ABBVIE: MAJOR PRODUCT OFFERINGS
TABLE 92 BOEHRINGER INGELHEIM: MAJOR PRODUCT OFFERINGS
TABLE 93 BRISTOL-MYERS SQUIBB COMPANY: MAJOR PRODUCT OFFERINGS
TABLE 94 CIPLA: MAJOR PRODUCT OFFERINGS
TABLE 95 ELI LILLY AND COMPANY: MAJOR PRODUCT OFFERINGS
TABLE 96 GSK: MAJOR PRODUCT OFFERINGS
TABLE 97 MERCK KGAA: MAJOR PRODUCT OFFERINGS
TABLE 98 NOVARTIS: MAJOR PRODUCT OFFERINGS
TABLE 99 PFIZER: MAJOR PRODUCT OFFERINGS
TABLE 100 SANOFI: MAJOR PRODUCT OFFERINGS
TABLE 101 SUN PHARMACEUTICAL INDUSTRIES: MAJOR PRODUCT OFFERINGS
TABLE 102 MYLAN: MAJOR PRODUCT OFFERINGS
TABLE 103 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 ($ BILLION)
TABLE 104 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 (%)
TABLE 105 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 ($ BILLION)
TABLE 106 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 (%)
TABLE 107 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 ($ BILLION)
TABLE 108 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 (%)
TABLE 109 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 ($ BILLION)
TABLE 110 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 (%)
TABLE 111 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 ($ BILLION)
TABLE 112 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 (%)
TABLE 113 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 ($ BILLION)
TABLE 114 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MOLECULE TYPE 2022–2028 (%)
TABLE 115 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 ($ BILLION)
TABLE 116 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 (%)
TABLE 117 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 ($ BILLION)
TABLE 118 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 (%)
TABLE 119 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 ($ BILLION)
TABLE 120 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 (%)
TABLE 121 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 ($ BILLION)
TABLE 122 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 (%)
TABLE 123 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 ($ BILLION)
TABLE 124 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 (%)
TABLE 125 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 ($ BILLION)
TABLE 126 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY THERAPY AREA 2022–2028 (%)
TABLE 127 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 ($ BILLION)
TABLE 128 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 (%)
TABLE 129 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 ($ BILLION)
TABLE 130 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 (%)
TABLE 131 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 ($ BILLION)
TABLE 132 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 (%)
TABLE 133 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 ($ BILLION)
TABLE 134 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 (%)
TABLE 135 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 ($ BILLION)
TABLE 136 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 (%)
TABLE 137 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 ($ BILLION)
TABLE 138 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURER TYPE 2022–2028 (%)
TABLE 139 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 ($ BILLION)
TABLE 140 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 (%)
TABLE 141 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 ($ BILLION)
TABLE 142 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 (%)
TABLE 143 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 ($ BILLION)
TABLE 144 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 (%)
TABLE 145 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 ($ BILLION)
TABLE 146 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 (%)
TABLE 147 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 ($ BILLION)
TABLE 148 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 (%)
TABLE 149 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 ($ BILLION)
TABLE 150 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BRAND 2022–2028 (%)
TABLE 151 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 ($ BILLION)
TABLE 152 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 (%)
TABLE 153 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 ($ BILLION)
TABLE 154 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 (%)
TABLE 155 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 ($ BILLION)
TABLE 156 APAC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 (%)
TABLE 157 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 ($ BILLION)
TABLE 158 EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 (%)
TABLE 159 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 ($ BILLION)
TABLE 160 LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 (%)
TABLE 161 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 ($ BILLION)
TABLE 162 MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY POTENCY 2022–2028 (%)
TABLE 163 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 164 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 165 GLOBAL SMALL MOLECULES/CHEMICAL APIS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 166 GLOBAL SMALL MOLECULES/ CHEMICAL APIS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 167 GLOBAL LARGE MOLECULES/BIOLOGICAL APIS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 168 GLOBAL LARGE MOLECULES/BIOLOGICAL APIS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 169 GLOBAL CARDIOVASCULAR ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 170 GLOBAL CARDIOVASCULAR ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 171 GLOBAL ONCOLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 172 GLOBAL ONCOLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 173 GLOBAL NEUROLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 174 GLOBAL NEUROLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 175 GLOBAL ANTI-INFECTIVES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 176 GLOBAL ANTI-INFECTIVES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 177 GLOBAL ENDOCRINOLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 178 GLOBAL ENDOCRINOLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 179 GLOBAL PULMONOLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 180 GLOBAL PULMONOLOGY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 181 GLOBAL OTHER THERAPY AREAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 182 GLOBAL OTHER THERAPY AREAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 183 GLOBAL CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 184 GLOBAL CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 185 GLOBAL MERCHANT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 186 GLOBAL MERCHANT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 187 GLOBAL PATENTED/INNOVATIVE APIS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 188 GLOBAL PATENTED/INNOVATIVE APIS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 189 GLOBAL GENERIC APIS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 190 GLOBAL GENERIC APIS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 191 GLOBAL NON-POTENT APIS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 192 GLOBAL NON-POTENT APIS MARKET BY GEOGRAPHY 2022–2028 (%)
TABLE 193 GLOBAL HIGHLY POTENT APIS MARKET BY GEOGRAPHY 2022–2028 ($ BILLION)
TABLE 194 GLOBAL HIGHLY POTENT APIS MARKET BY GEOGRAPHY 2022–2028 (%)
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
